Free tool
Drug Trial Radar: Kidney and urology
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
218
Completed, industry sponsors, Kidney and urology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed218
218 trials
Showing 1 to 25, recently updated first.
EHL Bio Co., Ltd.Industry
NCT06071143 · 6 participants · Start Feb 29, 2024 · Primary completion Mar 9, 2026
Drug: KDSTEM Inj. · For: Chronic Kidney Diseases
Sites: Daejeon, South Korea
BayerBayer (BAYRY)
NCT07722585 · 16 participants · Start Jul 28, 2026 · Primary completion Oct 12, 2026
Drug: Nurandociguat (BAY3283142) old tablet - SD; Nurandociguat (BAY3283142) new tablet - SD and 2 more · For: Chronic Kidney Disease
Sites: Berlin, Germany
- Phase 1 Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Chronic Kidney DiseaseCompleted
Pharmicell Co., Ltd.Industry
NCT05042206 · 10 participants · Start Nov 24, 2021 · Primary completion Sep 21, 2023
Drug: Cellgram-CKD · For: Chronic Kidney Disease
Sites: Seoul, South Korea
- Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fasting ConditionsCompleted
AJU Pharm Co., Ltd.Industry
NCT07643220 · 45 participants · Start Jun 27, 2026 · Primary completion Jul 29, 2026
Drug: Test Drug; Reference Drug · For: Moderate-to-severe Benign Prostatic Hyperplasia (BPH)
Sites: Seoul, South Korea
Inozyme PharmaIndustry
NCT06283589 · 11 participants · Start Feb 12, 2024 · Primary completion Jul 27, 2024
Drug: INZ-701 · For: Calciphylaxis
Sites: Coral Springs, Florida; Hollywood, Florida
Addpharma Inc.Industry
NCT07103278 · 44 participants · Start Jan 22, 2026 · Primary completion Mar 7, 2026
Drug: AD-116; AD-1161 · For: Benign Prostatic Hyperplasia
Sites: Seoul, South Korea
- A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846Completed
Chong Kun Dang PharmaceuticalIndustry
NCT07404735 · 34 participants · Start Feb 23, 2026 · Primary completion Jun 2, 2026
Drug: CKD-846; D091 · For: Benign Prostate Hypertrophy(BPH)
Sites: Seoul, South Korea
Boehringer IngelheimBoehringer Ingelheim
NCT04176536 · 28 participants · Start Dec 10, 2019 · Primary completion Nov 17, 2020
Drug: BI 764198 · For: Healthy; Chronic Kidney Disease
Sites: Kiel, Germany
- A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood PressureCompleted
BayerBayer (BAYRY)
NCT06428825 · 75 participants · Start Aug 16, 2024 · Primary completion Nov 21, 2025
Drug: BAY3283142; Placebo to BAY3283142 · For: Chronic Kidney Disease; Arterial Hypertension
Sites: Mannheim, Germany; Berlin, Germany
- Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03945318 · 103 participants · Start Apr 8, 2019 · Primary completion Jun 10, 2026
Drug: BION-1301 Single Dose; Placebo Single Dose and 3 more · For: IgA Nephropathy
Sites: Northridge, California; Denver, Colorado; Orlando, Florida · 16 sites in all
TakedaTakeda (TAK)
NCT05174221 · 17 participants · Start Aug 16, 2022 · Primary completion Dec 15, 2025
Drug: Mezagitamab · For: Kidney Disease; Glomerulonephritis
Sites: Northridge, California; Nampa, Idaho; Evanston, Illinois · 26 sites in all
- Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal DiseaseCompleted
Arrowhead PharmaceuticalsIndustry
NCT05083364 · 62 participants · Start Feb 1, 2022 · Primary completion Sep 10, 2025
Drug: ARO-C3; Placebo · For: C3 Glomerulopathy; IgA Nephropathy
Sites: Camperdown, Australia; Concord, Australia; Clayton, Australia · 16 sites in all
Arrowhead PharmaceuticalsIndustry
NCT06209177 · 49 participants · Start Apr 5, 2024 · Primary completion Mar 31, 2025
Drug: ARO-CFB; Placebo · For: IgA Nephropathy
Sites: Auckland, New Zealand
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT03719443 · 51 participants · Start Oct 9, 2018 · Primary completion Aug 10, 2019
Drug: VIS649; Placebo · For: Immunoglobulin A Nephropathy; IgAN - IgA Nephropathy; IgA Nephropathy
Sites: Glendale, California
Disc Medicine, IncIndustry
NCT05745883 · 55 participants · Start Apr 4, 2023 · Primary completion Oct 9, 2025
Drug: DISC-0974; Placebo · For: Chronic Kidney Diseases; Anemia of Chronic Kidney Disease
Sites: Los Angeles, California; Lone Tree, Colorado; DeLand, Florida · 13 sites in all
AstraZenecaAstraZeneca (AZN)
NCT07404137 · 26 participants · Start Feb 16, 2026 · Primary completion Apr 2, 2026
Drug: Zibotentan/Dapagliflozin FDC · For: Healthy Participants
Sites: Glendale, California
AstraZenecaAstraZeneca (AZN)
NCT06693765 · 41 participants · Start Nov 18, 2024 · Primary completion Apr 23, 2025
Drug: AZD4144 · For: Renal Impairment; End-stage Kidney Disease; Healthy Participants
Sites: Sofia, Bulgaria; Bucharest, Romania
- A Study to See How Safe a New Medicine (NNC0705-0001) is in Healthy PeoplePivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07029568 · 116 participants · Start Jun 13, 2025 · Primary completion Nov 4, 2025
Drug: NNC0705-0001; Placebo · For: Healthy Volunteers; Chronic Kidney Disease
Sites: Groningen, Netherlands
- A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846Completed
Chong Kun Dang PharmaceuticalIndustry
NCT06110923 · 31 participants · Start Nov 13, 2023 · Primary completion May 10, 2024
Drug: CKD-846; D091 · For: Benign Prostate Hypertrophy(BPH)
Sites: Seoul, South Korea
Tanabe Pharma CorporationIndustry
NCT01976572 · 18 participants · Start Oct 2013 · Primary completion Jan 2014
Drug: colestilan; candesartan · For: Hyperphosphatemia; Chronic Kidney Disease
Sites: Leeds, United Kingdom
Novo Nordisk A/SNovo Nordisk (NVO)
NCT05379829 · 24 participants · Start May 30, 2022 · Primary completion Jun 12, 2024
Drug: Ziltivekimab; Placebo · For: Chronic Kidney Disease and Systemic Inflammation
Sites: Beijing, China; Nanjing, China; Suzhou, China · 7 sites in all
KBP BiosciencesIndustry
NCT02837237 · 11 participants · Start Jul 13, 2016 · Primary completion Dec 20, 2016
Drug: KBP-5074 · For: Chronic Kidney Disease
Sites: Princeton, New Jersey
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT06490991 · 16 participants · Start Jul 17, 2024 · Primary completion Aug 6, 2024
Drug: HRS-5965 tablets;HRS-5965 capsules · For: Paroxysmal Nocturnal Hemoglobinuria,IgA Nephropathy
Sites: Shanghai, China
AstraZenecaAstraZeneca (AZN)
NCT06715670 · 30 participants · Start Dec 5, 2024 · Primary completion Feb 28, 2025
Drug: Zibotentan · For: Liver Cirrhosis
Sites: Glendale, California
AstraZenecaAstraZeneca (AZN)
NCT06675175 · 29 participants · Start Dec 9, 2024 · Primary completion Oct 27, 2025
Drug: AZD4144 · For: Chronic Kidney Disease; Atherosclerotic Cardiovascular Disease
Sites: Glendale, California; Daytona Beach, Florida; Jacksonville, Florida · 15 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.